Patients’ general characteristics.

<p>Patients’ general characteristics.</p

Genotype and allele frequencies of evaluated SNPs.

<p>Genotype and allele frequencies of evaluated SNPs.</p

Patients’ characteristics.

<p>Patients’ characteristics.</p

Ki67 change between 1^st and 2^nd histological evaluation.

<p>SI-NENs = circles. PNENs = squares. Horizontal reference lines refer to Ki67 cut-off levels for G1 NENs (2%) and G2 NENs (20%).</p

Progression free survival (PFS, expressed in months) according to selected VEGF-A, VEGFR-2 and VEGFR-3 polymorphisms.

<p>a) VEGF-A polymorphisms. b) VEGFR-2 polymorphisms. c) VEGFR-3 polymorphisms. d) Poor group (patients presenting all 3 polymorphisms) vs not poor group (patients presenting 1 or 2 polymorphisms). e) High-risk group (patients presenting all 3 polymorphisms) vs intermediate-risk group (patients presenting 2 polymorphisms) vs low-risk group (patients presenting at most 1 polymorphisms).</p

Surgical and medical history of the enrolled patients.

<p>Surgical and medical history of the enrolled patients.</p

Chromosomal location, position in the gene, effect and codon/aminoacid exchange of polymorphism studied group.

<p>Chromosomal location, position in the gene, effect and codon/aminoacid exchange of polymorphism studied group.</p